Bloodborne markers for prostate cancer have been known for almost 70 years but many have lacked specificity. The development of the prostate-specific antigen (PSA) blood test as a surrogate marker for disease in the 1980s has revolutionized the diagnosis and management of prostate cancer. Level...
The broad spectrum of numerous other markers for PCa that have been described (in serum, whole blood, molecular urine markers [RNA, DNA and protein], and cellular?genetic tests) are discussed. The evidence for some of the more promising biomarkers (including circulating tumor cells [CTC] in ...
thus supervised analyses were performed to extract possible cancer-related information masked by the large metabolic variations in blood. To discriminate cancer patients from controls and to assess correlations to clinical parameters, multivariate analysis was performed on autoscaled quantified data by ortho...
for prostate cancer Blood-based biomarkers for prostate cancerBlood-based biomarkers for prostate cancerV.M., VelonasC.D., RemediosH., WooJ.W.K., HoS., AssinderBju International
DNA-based detection of prostate cancer in blood, urine, and ejaculates. Krause, and K. Miller, "Dna-based detection of prostate cancer in blood, urine, and ejaculates," Ann N Y Acad Sci, vol. 945, pp. 51-8, 2001... C Goessl,M Müller,R Heicappell,... - 《Ann N Y Acad Sci...
Potential of Raman Spectroscopy for Blood-Based Biopsy Current blood diagnostic assays, however, typically detect single biomarkers (e.g., pH [3], prostate specific antigen (PSA) in prostate cancer, cancer ... C Ciobanu,KJI Ember,BJ Nyiri,... - 《IEEE Instrumentation & Measurement Magazine》...
“Webinar delivered in Spanish with subtitles in Portuguese” In 2022, there were approximately 1.4 million new cases of prostate cancer reported globally and over 397,000 deaths reported globally. Prostate cancer can be found early in asymptomatic men using a simple, safe, and inexpensive blood te...
Reliable prognostic biomarkers to distinguish indolent from aggressive prostate cancer (PCa) are lacking. Many studies investigated microRNAs (miRs) as PCa prognostic biomarkers, often reporting inconsistent findings. We present a systematic review of th
Hence, there is a need for new markers that better differentiate benign from malignant lesions and indolent from aggressive cancers to decrease the potential over treatment of prostate cancer. With recent advances in biotechnology, many promising blood biomarkers have been identified and are currently ...
One test examines a person's blood for four biomarkers linked to inflammation. In a small study, it outperformed the fecal blood test now used in colon cancer screening, said lead researcher Dr. Mona Eldeeb, of Alexandria University Medical Research Institute in Egypt. ...